Decoding F508del Misfolding in Cystic Fibrosis

被引:10
|
作者
Wang, Xiaodong Robert [1 ]
Li, Chenglong [2 ]
机构
[1] Samford Univ, McWhorter Sch Pharm, Dept Pharmaceut, Social & Adm Sci, 800 Lakeshore Dr, Birmingham, AL 35229 USA
[2] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Columbus, OH 43210 USA
来源
BIOMOLECULES | 2014年 / 4卷 / 02期
关键词
ABC transporter; CFTR; cystic fibrosis; drug discovery; F508del; molecular dynamics simulation; nucleotide-binding domain; protein conformation; protein folding; protein stability;
D O I
10.3390/biom4020498
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The functional deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR), a plasma membrane chloride channel, leads to the development of cystic fibrosis. The deletion of a phenylalanine at residue 508 (F508del) is the most common cause of CFTR misfolding leading to the disease. The F508del misfolding originates in the first nucleotide-binding domain (NBD1), which induces a global conformational change in CFTR through NBD1's interactions with other domains. Such global misfolding produces a mutant chloride channel that is impaired in exocytic trafficking, peripheral stability, and channel gating. The nature and atomic details of F508del misfolding have been subject to extensive research during the past decade. Current data support a central role for NBD1 in F508del misfolding and rescue. Many cis-acting NBD1 second-site mutations rescue F508del misfolding in the context of full-length CFTR. While some of these mutations appear to specifically counteract the F508del-induced misfolding, others release certain inherent conformational constraints of the human wild-type CFTR. Several small-molecule correctors were recently found to act on key interdomain interfaces of F508del CFTR. Potential rational approaches have been proposed in an attempt to develop highly effective small molecule modulators that improve the cell surface functional expression of F508del CFTR.
引用
收藏
页码:498 / 509
页数:12
相关论文
共 50 条
  • [31] Genes in the vicinity of CFTR modulate the cystic fibrosis phenotype in highly concordant or discordant F508del homozygous sib pairs
    Frauke Mekus
    Ulrike Laabs
    Henk Veeze
    Burkhard Tümmler
    Human Genetics, 2003, 112 : 1 - 11
  • [32] Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real-Life Study
    Zwitserloot, A. M.
    Aziz, S. Z.
    Chen, Y.
    Bannier, M. A. G. E.
    Janssens, H. M.
    Merkus, P. F. J. M.
    Nuijsink, M.
    Terheggen-Lagro, S. W. J.
    Tiddens, H. A. W. M.
    Zomer- van Ommen, D. D.
    Vonk, J. M.
    de Winter- de Groot, K. M.
    Willemse, B. W. M.
    Koppelman, G. H.
    PEDIATRIC PULMONOLOGY, 2025, 60 (01)
  • [33] Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients
    Yaacoby-Bianu, Karin
    Schnapp, Zeev
    Koren, Ilana
    Ilivitzki, Anat
    Khatib, Mohamed
    Shorbaji, Nadeem
    Shteinberg, Michal
    Livnat, Galit
    BMC PHARMACOLOGY & TOXICOLOGY, 2022, 23 (01)
  • [34] Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles
    Graeber, Simon Y.
    Vitzthum, Constanze
    Pallenberg, Sophia T.
    Naehrlich, Lutz
    Stahl, Mirjam
    Rohrbach, Alexander
    Drescher, Marika
    Minso, Rebecca
    Ringshausen, Felix C.
    Rueckes-Nilges, Claudia
    Klajda, Jan
    Berges, Julian
    Yu, Yin
    Scheuermann, Heike
    Hirtz, Stephanie
    Sommerburg, Olaf
    Dittrich, Anna-Maria
    Tuemmler, Burkhard
    Mall, Marcus A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205 (05) : 540 - 549
  • [35] Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients
    Karin Yaacoby-Bianu
    Zeev Schnapp
    Ilana Koren
    Anat Ilivitzki
    Mohamed Khatib
    Nadeem Shorbaji
    Michal Shteinberg
    Galit Livnat
    BMC Pharmacology and Toxicology, 23
  • [36] VIP reduction in the pancreas of F508del homozygous CF mice and early signs of Cystic Fibrosis Related Diabetes (CFRD)
    Semaniakou, Anna
    Chappe, Frederic
    Anini, Younes
    Chappe, Valerie
    JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (05) : 881 - 890
  • [37] Airway Delivery of Low-Dose Miglustat Normalizes Nasal Potential Difference in F508del Cystic Fibrosis Mice
    Lubamba, Bob
    Lebacq, Jean
    Lebecque, Patrick
    Vanbever, Rita
    Leonard, Anissa
    Wallemacq, Pierre
    Leal, Teresinha
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179 (11) : 1022 - 1028
  • [38] Characterization of two rat models of cystic fibrosis—KO and F508del CFTR—Generated by Crispr-Cas9
    Elise Dreano
    Marc Bacchetta
    Juliette Simonin
    Louise Galmiche
    Claire Usal
    Lotfi Slimani
    Jérémy Sadoine
    Laurent Tesson
    Ignacio Anegon
    Jean-Paul Concordet
    Aurélie Hatton
    Lucile Vignaud
    Danielle Tondelier
    Isabelle Sermet-Gaudelus
    Marc Chanson
    Charles-Henry Cottart
    Animal Models and Experimental Medicine, 2019, 2 (04) : 297 - 311
  • [39] Synonymous Codon Usage Affects the Expression of Wild Type and F508del CFTR
    Shah, Kapit
    Cheng, Yi
    Hahn, Brian
    Bridges, Robert
    Bradbury, Neil A.
    Mueller, David M.
    JOURNAL OF MOLECULAR BIOLOGY, 2015, 427 (06) : 1464 - 1479
  • [40] ADVANCES IN TREATING PATIENTS HOMOZYGOUS FOR F508DEL
    Taylor-Cousar, Jennifer L.
    Elborn, Stuart
    PEDIATRIC PULMONOLOGY, 2017, 52 : S173 - S175